Plerixafor given before the third leukapheresis to rescue an unsuccessful stem cell mobilization with CY and G-CSF

Bone Marrow Transplantation

Volumn 45, Issue 6, 2010, Pages 1121-1122

  Nimmagadda, S ^a   Sweiss, K ^a   Mahmud, N ^a   Park, Y ^a   Rondelli, D ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CARMUSTINE; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; METHOTREXATE; PLERIXAFOR; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOSPORIN; GRANULOCYTE COLONY STIMULATING FACTOR; HETEROCYCLIC COMPOUND; IMMUNOSUPPRESSIVE AGENT;

ABNORMAL LABORATORY RESULT; ADULT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CARDIOTOXICITY; CASE REPORT; CLINICAL FEATURE; DOSE RESPONSE; DRUG MEGADOSE; HEMATOLOGIC DISEASE; HUMAN; LARGE CELL LYMPHOMA; LETTER; LEUKAPHERESIS; LEUKOCYTE COUNT; LYMPHADENOPATHY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SALVAGE THERAPY; STEM CELL MOBILIZATION; THROMBOCYTOPENIA; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PROCEDURES;

ANTI-HIV AGENTS; CYCLOSPORINE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKAPHERESIS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED;

EID: 77954862917     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.295     Document Type: Letter

References (11)

1. Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO et al. Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406-413.
2. Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399-2404.
3. Lemoli RM, de Vivo A, Damiani D, Isidori A, Tani M, Bonini A et al. Autologous transplantation of granulocyte colonystimulating factor-primed bone marrow is effective to support myeloablative chemotherapy in patients with hematological malignancies and poor peripheral blood stem cell mobilization. Blood 2003; 102: 1595-1600.
4. Wagstaff AJ. Plerixafor: in patients with non-Hodgkin's lymphoma or multiple myeloma. Drugs 2009; 69: 319-326.
5. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. BoneMarrow Transplant 2009. (e-pub ahead of print 1 June 2009; doi:10.1038/bmt.2009.119).
6. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874.
7. DiPersio JF, Bridger G, Calandra G. Effect of Plerixafor (AMD3100) plus G-CSF on tumor cell mobilization among patients with lymphoma. Biol Blood Marrow Transplant 2009; 15 (Suppl 2): a90.
8. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
9. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004; 103: 3684-3688.
10. Thomas DA, Faderl S, O'Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569-1580.
11. Caballero MD, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997; 20: 451-458.